Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LNC1011
- Development stage
- Unknown
- Lead developer
- Affiliated Hospital of Southwest Medical University
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
LNC1011 is a radiopharmaceutical ligand designed to target Prostate-Specific Membrane Antigen (PSMA), which is highly expressed in prostate cancer cells. Developed by researchers at The Affiliated Hospital of Southwest Medical University, LNC1011 serves as a targeting vector for radionuclide therapy. It can be chelated with various radioisotopes, most notably Lutetium-177 (177Lu) for beta-particle therapy and Actinium-225 (225Ac) for alpha-particle therapy. The agent is currently being evaluated in exploratory clinical trials (Phase 0) to assess its safety, biodistribution, and radiation dosimetry in patients with PSMA-positive prostate cancer, aiming to provide a more effective and targeted treatment option for metastatic castration-resistant prostate cancer (mCRPC).
- Other names
- 177Lu-LNC1011225Ac-LNC1011
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on LNC1011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LNC1011.